P

paraneoplastic syndromes, 1163 pentostatin, 662 peptic ulcer disease, 2 periodic acid—Schiff (PAS) (erythroid), 33 peripheral T-cell lymphoma autologous hematopoietic cell transplantation for, 679-698 unspecified (PTCLU), 521-522 p-glycoprotein efflux pump, 56

p-glycoprotein (gp170) chemotherapy efflux pump, 51

phenylbutyrate, 97

Philadelphia chromosome, t(9;22), 35

phlebotomies, 470

PI-3 kinase, 97

PKC412, 78, 97

PML-RARA gene, 10-11

expression, in AML, 20 Pneumocystis carinii pneumonia, 67 polyclonal hairy B-cell lymphoproliferative disorder, 282 polycythemia vera (PV), 462-464 cytogenetics, 451 diagnosis of, 469-470 incidence and clinical presentation, 469 molecular biology, 451 pathology of, 451 survival, 469 treatment of, 470-471 polymerase chain reaction (PCR), 238, 488 postpolycythemic myeloid metaplasia (PPMM), 475 postremission chemotherapy, 43-44, 57-59 postremission therapy, 43-44 postthrombocythemic (PTMM), 475 posttransplant lymphoproliferative disorders clinical features, 647 evaluation, 647-650 incidence and risk factors, 646-647 management of adoptive immunotherapy, 653 anti-B cell therapy, 651-652 anti-interleukin 6 therapy, 653 antiviral therapy, 653-654 arginine butyrate, 653 chemotherapy, 652-653

decreasing immunosuppressive therapy, 650-651 interferon alpha therapy, 654 rapamycin, 652 pathophysiology, 645-646 precursor B-cell and T-cell lymphoblastic lymphoma clinical features, 565-566 frequency of occurence, 565 pathology and pathogenesis, 566 prognostic factors, 566-567 radiation therapy, 567 stem cell transplantation, 567-569 treatment of, 567 precursor cell tumors, 508 prednisone, 3

pregnant women, treatment approach to diagnosis of, 1149

impact of pregnancy on leukemia, 1147-1148 passage of leukemic cells to fetus, 1149 pharmacokinetics with, 1149-1150 physiological changes with pregnancy, 1147

pregnant women, treatment approach to (continued) placental function, 1148-1149

teratogenicity of chemotherapeutic agents, 1150-1152 treatment of specific hematologic malignancies acute leukemias, 1152-1153 chronic lymphocytic leukemia, 1155 chronic myelogenous leukemia, 1154-1155 hairy-cell leukemia, 1155

human T-cell lymphotrophic virus type I, 1155-1156 myelodysplastic syndromes (MDS), 1153-1154 primary central nervous system lymphoma clinical characteristics, 589-591 definition of, 589 epidemiology, 589 pathology, 589 primary treatment chemotherapy alone, 594-596

chemotherapy in combination with WBXRT, 592-594 corticosteroids, 591 neurotoxicity, 594 surgery, 591

whole brain irradiation, 591-592 relapsed or refractory, treatment of, 596-597 special therapeutic circumstances intraocular lymphoma, 596 leptomeningeal lymphoma, 596 special lymphoma, 596 primary cutaneous B-cell lymphoma, treatment of chemotherapy, 602-603 peripheral stem cell transplantation, 603 radiation therapy, 601-602 recommended treatment approaches for, 603 surgery, 602

primary cutaneous CD30 positive lymphoproliferative disorders, 525-526

primary cutaneous T-cell lymphoma, treatment of of advanced stage mycosis fungoides/Sézary syndrome, 605 biologic response modifiers, 605 of CD30 positive lymphoproliferative disorders, 607 early stage mycosis fungoides, 603-604 extra corporeal photochemotherapy, 606 interferon-alpha therapy, 605-606 peripheral stem cell transplantation, 607 phototherapy/ photochemotherapy, 604 recommended treatment approaches, 604-605 retinoids, 606

of small and medium pleomorphic

T-cell lymphoma, 607 systemic chemotherapy, 605 topical chemotherapy, 604 topical retinoid application, 604 topical steroids, 604 total skin electron beam therapy, 604 trageted modalities, 606 primary effusion lymphoma, 521 primary induction failure, 91 procarbazine, 3 promyelocytes, 31

prophylactic platelet transfusions, 488 proteoglycans, 475 PSC 833, 56 PTK787, 76

purine nucleosides, 296-297 Q

11q23 gene, 35

quality of life measurements, 77 R

R115977, 78, 97

RAB5EP/PDGFRÇ, fusion gene, 490 RAS mutations, in AML patients, 20 receptor tyrosine kinases (RTKs), 487

reduced-intensity stem cell transplantation in CML, 359 Reed-Sternberg cells, 752, 810 refractory anemia with excess blasts in transformation (RAEBt), 490 refractory anemia with excess blasts (RAEB), 490 Reike, 59

relapsed leukemia, 45-46 remission induction therapy, in AML, 53-59, 83 additional induction agents, 56-57 anthracenediones, 54-56 anthracyclines, 54-56 gemtuzumab ozogamicin, 57 post-remission stem cell transplantation, 59 post remission therapy, 57-59 protracted post-remission therapy, 59 varying doses of anthracyclines, 56 renal insufficiency, 964-965 renal syndromes, 1163-1164 reticulin fibrosis, 475 retinoic acid receptor a (RARA) gene, 17 retinoic acid receptor a (PAPA)yeve, 63 retinoids, 1108-1110

reverse transcriptase polymerase chain reaction (RT-PCR)

techniques, 84 reverse transcription polymerase chain reaction (RT-PCR), 9, 104

rheumatoid arthritis, 2, 837

Richter's syndrome, 718-719

rituximab, 304, 723

Romanowsky stains, 9

Royal Marsden criteria, 35

RUNXI mutations, in AML patients, 19

0 0

Post a comment